ReviewDrug design, development and therapy2017
Radium 223 dichloride for prostate cancer treatment.
Review in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 97 citations in OpenAlex.
- Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.Breast cancer research and treatment · 2024Trial
- Hijacking the bone niche: mechanistic insights into bone metastasis in breast cancer.Bone research · 2026Review
- Biokinetic modelling of the exhalation ofRadiation and environmental biophysics · 2026Article
- Chemical Tools to Characterize the Coordination Chemistry of Radionuclides for Radiopharmaceutical Applications.Chemical reviews · 2025Review
- [Options in nuclear medicine for advanced prostate cancer in practice].Radiologie (Heidelberg, Germany) · 2025Article
- [Options in nuclear medicine for advanced prostate cancer in practice].Urologie (Heidelberg, Germany) · 2025Review
- Review
- The Tight Relationship Between the Tumoral Microenvironment and Radium-223.Biomedicines · 2025Review
- Current status of radionuclide therapies in metastatic castration-resistant prostate cancer.Therapeutic advances in medical oncology · 2025Review
- Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects duringTheranostics · 2025Review
- Chemistry of Antimony in Radiopharmaceutical Development: Unlocking the Theranostic Potential of Sb Isotopes.ChemPlusChem · 2024Review
- Recent advances and future perspectives in the therapeutics of prostate cancer.Experimental hematology & oncology · 2023Article
- Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment.Diagnostics (Basel, Switzerland) · 2023Article
- Laser isotope separation ofScientific reports · 2023Article
- A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer.Frontiers in oncology · 2023Review
- Resveratrol used as nanotherapeutic: a promising additional therapeutic tool against hormone-sensitive, hormone-insensitive and resistant prostate cancer.American journal of clinical and experimental urology · 2023Review
- A Projection-Domain Low-Count Quantitative SPECT Method forIEEE transactions on radiation and plasma medical sciences · 2023Article
- Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer.SAGE open medicine · 2023Article
- Article
- FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.